We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

ThromboGenics and BioInvent Start Phase II Trial of TB-402 for Deep Vein Thrombosis Prophylaxis

News   Feb 24, 2009

 
ThromboGenics and BioInvent Start Phase II Trial of TB-402 for Deep Vein Thrombosis Prophylaxis
 
 
Advertisement
 

RELATED ARTICLES

Blood Markers of Fitness Identified

News

A simple blood test may be able to determine how physically fit you are, according to a new study conducted by scientists at the Stanford University School of Medicine.

READ MORE

FDA Grants Fast Track Designation to Onvansertib for Second-line Treatment of KRAS-mutated Colorectal Cancer

News

The U.S. Food and Drug Administration (FDA) has granted Fast Track Designation to onvansertib, an oral and highly-selective Polo-like Kinase 1 (PLK1) inhibitor, for the second-line treatment of patients with KRAS-mutated metastatic colorectal cancer.

READ MORE

Solving the Medical Mystery of Anesthesia

News

Researchers have solved the longstanding mystery of the mechanisms behind the effects of anesthetics.

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Drug Discovery Proteomics & Metabolomics

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE